Form 4: Jaguar Health CFO Granted Equity Awards

Jaguar Health's Chief Financial Officer, Carol R. Lizak, was granted 11,740 restricted stock units and 11,740 stock options on December 11, 2025.

Summary

• Carol R. Lizak, Chief Financial Officer of Jaguar Health, Inc. (JAGX), was granted equity awards on December 11, 2025.
• The awards include 11,740 shares of Common Stock in the form of Restricted Stock Units (RSUs) and 11,740 Stock Options.
• The RSUs were granted pursuant to the issuer's 2014 Stock Incentive Plan and represent a contingent right to receive one share of voting common stock per unit.
• The RSUs will vest on December 11, 2026, with vested shares delivered on that date.
• The stock options have an exercise price of $1.44 per share and were also granted under the 2014 Stock Incentive Plan.
• The options will vest ratably on a monthly basis over 12 months from the grant date (December 11, 2025), provided the executive remains employed.
• The options have an expiration date of December 11, 2035.
• Following these transactions, Carol R. Lizak beneficially owns 11,911 shares of Common Stock directly and 11,740 derivative securities (stock options) directly.
• The issuer effected a 25-for-1 reverse stock split of its voting common stock on March 24, 2025.

Sentiment

Score: 7

Explanation: The filing reports a routine executive compensation event, which is generally positive for corporate governance by aligning management incentives with shareholder interests. It does not contain information that would significantly alter the company's fundamental outlook.

Positives

• The equity grants align the Chief Financial Officer's interests with those of shareholders, incentivizing long-term performance and value creation.
• The grants are part of a structured compensation plan (2014 Stock Incentive Plan), indicating a formal approach to executive incentives.

Future Outlook

The equity grants are designed to incentivize the Chief Financial Officer's continued employment and contribution to the company's performance, with vesting tied to future dates and ongoing service.

Management Comments

• The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.

Industry Context

Equity compensation, including restricted stock units and stock options, is a standard practice in publicly traded companies, particularly in the biotechnology and pharmaceutical sectors, to attract, retain, and motivate key executives by aligning their financial interests with long-term shareholder value.

Comparison to Industry Standards

• This equity compensation package for a Chief Financial Officer is consistent with standard practices observed across public companies, aiming to align executive incentives with shareholder interests.
• No specific comparable companies, projects, or results are mentioned in the filing to provide a direct, detailed comparison.

Corporate Governance

Related Party Transactions

• The grant of equity awards to Carol R. Lizak, the Chief Financial Officer, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of management's financial interests with long-term company performance.
• Employees (CFO): Direct financial benefit through equity compensation, contingent on continued employment and company performance.

Next Steps

• The granted Restricted Stock Units are scheduled to vest on December 11, 2026.
• The granted stock options will vest ratably on a monthly basis over 12 months from December 11, 2025.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation in the form of equity grants. While these grants align management incentives with shareholder interests, they do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate, pending further operational or financial updates.

Keywords

Jaguar Health, JAGX, SEC Form 4, Stock Option, Restricted Stock Unit, Equity Grant, CFO, Executive Compensation, Insider Transaction, Stock Incentive Plan